Physicians
Oncura provides minimally invasive treatments options
for prostate cancer. By bringing brachytherapy and
cryotherapy together we have created a unique capability
to serve patients, physicians and hospitals providing
both of these minimally invasive treatment options
through one company. In addition to this, Oncura also
offers cryotherapy to treat renal cancer.
In Prostate cancer, the two modalities are positioned
as complementary, with brachytherapy being used in
low and intermediate risk patients and cryotherapy
in radiation failure and high risk patients. At Oncura
we believe that there is a clear distinction backed
by supporting data. Brachytherapy has been successful
over a long period of time and has been established
as an effective treatment in the low and intermediate
risk groups as evidenced by peer-reviewed clinical
literature, whereas cryotherapy which is an emerging
technology, can be used in the higher risk patients
and radiation failures (where the recurrence is still
localized), and for groups of patients for whom there
is no real definitive option.
Risk Groups Localized Prostate Cancer
|
